The FDA has issued a Request for Information (RFI) asking for public input on potential standards for in-home opioid disposal products. The move aims to reduce risks associated with unused prescription opioids kept in American homes.
The request focuses on how patients can safely dispose of leftover opioid medications at home after treatment.
Unused opioid medications stored at home can increase the risk of misuse or accidental exposure, particularly among children, teenagers or individuals who were not prescribed the drugs.
The FDA currently advises patients to dispose of unused opioids through drug take-back programs or by mailing them back using prepaid envelopes provided by pharmacies or other dispensers.
For certain high-risk medications, the FDA also recommends flushing unused drugs when other options are not available. Research cited by the FDA has suggested that flushing unused opioids presents a negligible ecological risk, according to findings published in the journal Science of the Total Environment in 2017.
What the FDA Is Considering
The agency is exploring whether manufacturers of opioid analgesics should be required to provide in-home opioid disposal systems through pharmacies or other dispensing locations.
Currently, opioid sponsors must make prepaid mail-back envelopes available to outpatient pharmacies and other dispensers. The new effort seeks feedback on whether additional disposal options should be provided to help patients safely dispose of leftover medications at home.
Through the RFI, the FDA is asking stakeholders to provide input on appropriate criteria for in-home disposal products.
Related: FDA and EMA Align on Good AI Practice in Pharma
What It Means for Stakeholders
If additional requirements are introduced, opioid manufacturers, pharmacies and other dispensers could play a role in making in-home disposal systems available to patients receiving opioid prescriptions.
The approach would aim to reduce the number of unused opioid medications remaining in households while supporting broader efforts to address risks associated with unused prescription opioids.
The request aligns with the SUPPORT for Patients and Communities Reauthorization Act of 2025, which directs the FDA to facilitate safe in-home opioid disposal options. The initiative is also linked to broader federal efforts aimed at addressing the opioid crisis.
The FDA is inviting feedback from industry, healthcare providers, advocacy groups and other stakeholders. Public comments on the request for information are due April 6, 2026.
New Developments in the US Opioid Landscape
Several recent developments in the US relate to addiction treatment, opioid misuse and non-opioid pain therapies.
In February 2026, the US Department of Health and Human Services (HHS) announced a $100 million initiative called STREETS aimed at expanding outreach, treatment and housing support for individuals experiencing addiction and homelessness. The announcement also included a $10 million Assisted Outpatient Treatment grant program supporting court-ordered outpatient mental health treatment for adults with serious mental illness.
In clinical research, Sustained Therapeutics reported positive Phase II results for ST-01, a long-acting injectable therapy for chronic scrotal pain designed to provide non-opioid pain relief for about 28 days from a single injection.
Algia Pharma reported that the FDA supported advancing its AlgiaPak therapy toward a Phase II clinical trial following IND-enabling studies. The formulation combines multiple non-opioid medicines in a single treatment intended to treat mild-to-moderate acute pain.
In 2025, the first US patient received Neuros Medical’s FDA-approved Altius system, an implantable device that uses electrical nerve stimulation to treat chronic post-amputation pain. The system allows patients to initiate on-demand treatment sessions that block pain signals from damaged nerves.
And early last year, Vistagen received a patent for its investigational non-opioid candidate AV-101 for neuropathic pain. The patent extends protection for the program until at least 2034. The program has an FDA Fast Track designation.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN